Research Reports | Market Access
July 2023

Highmark | 2023 | National MCO Analyzer Brief

Highmark, along with 17 other Blue Cross Blue Shield organizations, invested $55 million to create their own nonprofit drug company with CivicaRx in 2020 to make alternatives to high-cost generic drugs at a more affordable price. The new CivicaRx subsidiary will begin by producing seven to 10 generic drugs that will hit the market in 2022. CivicaRx also teamed up with Sandoz (Novartis) for five years on July 7, 2020, to manufacture and supply six high-demand generic injectables to fight drug shortages. Also, look for HighmarkÕs new Living Health model to begin implementation in 2021 and 2022 after announcing multi-year collaboration agreements with technology platforms, Verily and Google Cloud. The Living Health model is meant to eliminate fragmentation in healthcare to provide seamless and personalized treatment plans to manage chronic conditions including heart failure and chronic obstructive pulmonary disease.

Login to access report
Back to all Market Access reports
Login to access report

launch Related Market Access Reports